ArticleTransfusion2025
Optimization of biotinylation protocol for next generation studies of red blood cell survival after transfusion.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical evaluation of novel blood collection and storage bags containing alternative plasticizers to DEHP: Recommendations from the BEST collaborative.Transfusion · 2025Article
- Assessing RBC transfusion efficacy in chronic transfusion recipients: advancing precision transfusion medicine.Blood transfusion = Trasfusione del sangueArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundRed blood cell (RBC) biotinylation has increasingly become the preferred method for quantifying RBC post-transfusion recovery (PTR). This study evaluated the feasibility of transfusing autologous RBCs labeled with biotin (BioRBCs) 48 h prior to transfusion. The rationale was to facilitate the distribution of BioRBC products from manufacturing sites to remote clinical sites. STUDY
designLeukocyte-reduced RBC units from 12 healthy individuals were stored at 1-6°C for 42 days and biotinylated with two biotin densities (3 and 15 μg/mL) 48 and 4 h prior to transfusion. Each individual was transfused with 10 mL of each BioRBC preparation, after which BioRBC 20 h PTR and long-term survival (30 and 90 days) were determined by flow cytometric analyses. Additional quality measurements included phosphatidylserine (PS) exposure on BioRBCs and in vitro metrics of hemolysis.
resultsRBC transfusion 48 h after biotinylation was not associated with altered BioRBC 20 h PTR or 30 and 90 day survival as compared with RBC transfusion 4 h after biotinylation (e.g., PTR 20 h: 85.7% ± 8.4% vs. 87.5% ± 7.3%; 48 and 4 h, respectively, p > .05). Similarly, no significant differences between the BioRBC groups were observed in BioRBC PS exposure at all time points. BioRBC long-term survival, but not 20 h PTR, was negatively associated with donor hemoglobin (Pearson r = -0.71, p = .001) and osmotic hemolysis (r = -0.783, p = .003). None of the participants developed antibodies against BioRBCs during the trial.
conclusionsRBC biotinylation 48 h prior to transfusion does not compromise the quality and safety of BioRBC products. BioRBC long-term survival can be used to identify donor characteristics that influence RBC lifespan in the circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.